Ospemifene, vulvovaginal atrophy, and breast cancer

被引：40

作者：

Wurz, Gregory T. ^{[1
]}

Soe, Lin H. ^{[2
]}

DeGregorio, Michael W. ^{[1
]}

机构：

[1] Univ Calif Davis, Dept Internal Med, Div Hematol & Oncol, Sacramento, CA 95817 USA

[2] Marshall Hosp, Cameron Pk, CA 95682 USA

来源：

MATURITAS | 2013年 / 74卷 / 03期

关键词：

Ospemifene; Breast cancer; Antiestrogen; Vulvovaginal atrophy; ESTROGEN-RECEPTOR MODULATORS; TRANSGENIC MOUSE MODEL; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; SIGNALING PATHWAYS; TISSUE-SPECIFICITY; MAMMARY-TUMORS; BONE TURNOVER; GENITAL-TRACT; TAMOXIFEN;

D O I：

10.1016/j.maturitas.2012.12.002

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted. Published by Elsevier Ireland Ltd.

引用

页码：220 / 225

页数：6

共 46 条

[1] Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study [J].

Bachmann, Gloria A. ;

Komi, Janne O. .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (03) :480-486

[2] Tamoxifen therapy for breast cancer and endometrial cancer risk [J].

Bernstein, L ;

Deapen, D ;

Cerhan, JR ;

Schwartz, SM ;

Liff, J ;

McGann-Maloney, E ;

Perlman, JA ;

Ford, L .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1654-1662

[3] Molecular basis of agonism and antagonism in the oestrogen receptor [J].

Brzozowski, AM ;

Pike, ACW ;

Dauter, Z ;

Hubbard, RE ;

Bonn, T ;

Engstrom, O ;

Ohman, L ;

Greene, GL ;

Gustafsson, JA ;

Carlquist, M .

NATURE, 1997, 389 (6652) :753-758

[4]

Burich R, 2014, EXPERT REV OBSTET GY, V6, P141, DOI [10.1586/EOG.11.3, DOI 10.1586/eog.11.3]

[5] Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model [J].

Burich, Rebekah A. ;

Mehta, Neelima Rakesh ;

Wurz, Gregory T. ;

McCall, Jamie Lee ;

Greenberg, Brittany E. ;

Bell, Katie E. ;

Griffey, Stephen M. ;

DeGregorio, Michael W. .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (01) :96-103

[6] Non-genomic effects of tamoxifen on the activation of membrane-bound guanylate cyclase GC-A [J].

Chen, ZJ ;

Vetter, M ;

Chang, GD ;

Liu, SG ;

Ding, YX ;

Chang, CH .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (11) :1539-1545

[7] Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women [J].

Chlebowski, Rowan T. ;

Anderson, Garnet L. ;

Gass, Margery ;

Lane, Dorothy S. ;

Aragaki, Aaron K. ;

Kuller, Lewis H. ;

Manson, JoAnn E. ;

Stefanick, Marcia L. ;

Ockene, Judith ;

Sarto, Gloria E. ;

Johnson, Karen C. ;

Wactawski-Wende, Jean ;

Ravdin, Peter M. ;

Schenken, Robert ;

Hendrix, Susan L. ;

Rajkovic, Aleksandar ;

Rohan, Thomas E. ;

Yasmeen, Shagufta ;

Prentice, Ross L. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (15) :1684-1692

[8] Update on alternative therapies for vulvovaginal atrophy [J].

Chollet, Janet A. .

PATIENT PREFERENCE AND ADHERENCE, 2011, 5 :533-536

[9] Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator [J].

DeGregorio, MW ;

Wurz, GT ;

Taras, TL ;

Erkkola, RU ;

Halonen, KH ;

Huupponen, RK .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (6-7) :469-475

[10] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].

Fisher, B ;

Costantino, JP ;

Wickerham, DL ;

Redmond, CK ;

Kavanah, M ;

Cronin, WM ;

Vogel, V ;

Robidoux, A ;

Dimitrov, N ;

Atkins, J ;

Daly, M ;

Wieand, S ;

Tan-Chiu, E ;

Ford, L ;

Wolmark, N .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388

← 1 2 3 4 5 →